| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Louis Edward Tamayo is Chief Financial Officer at LXEO. Louis Edward Tamayo's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $289K at current prices.
The LXEO filings lean toward selling, a net 8,758 shares.
Louis Edward Tamayo has 5 Form 4 filings on record from August 2025 to September 2026, all as Chief Financial Officer at Lexeo Therapeutics (LXEO), 2025–2026.
The 8 reported transactions were 3 option or other derivative awards, 3 stock awards and 2 open-market sales.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $41K.
The largest open-market sale was 4,641 shares of LXEO at an average $4.49 on July 1, 2026, about $21K.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.